Last update Sept. 26, 2014

アミノレブリン酸塩酸塩

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is locally used together with photo-dynamic therapy (especial blue light) as a treatment of Actinic Dermatitis and Basocelular Carcinoma.

At latest update, relevant information on excretion into breast milk was not found.

Absorption through the skin is very low (0.26 % of administered dose), hence, a low or non-significant level in the mother's plasma should be expected.

In case that a complete elimination of drug would be desired, a time period equivalent to ten times a half-life (Mean time) should be observed after drug administration to resume breastfeeding.

In this case it would be equal to 8-10 hours.

In the mean while, pump-and-dump regularly to maintain milk production.

Do not apply it on the breast or cleanse it thoroughly to keep the baby from swallowing.

Alternatives

We do not have alternatives for アミノレブリン酸塩酸塩.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

アミノレブリン酸塩酸塩 is also known as 5-Aminolevulinic Acid. Here it is a list of alternative known names::


Group

アミノレブリン酸塩酸塩 belongs to this group or family:

Tradenames

Main tradenames from several countries containing アミノレブリン酸塩酸塩 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 50 - 60 %
Molecular weight 131 daltons
0.8 hours

References

  1. EMEA. Ácido 5-aminolevulínico. Ficha técnica 2011 Full text (in our servers)
  2. Sandberg C, Halldin CB, Ericson MB, Larkö O, Krogstad AL, Wennberg AM. Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo. Br J Dermatol. 2008 Abstract
  3. McLoone N, Donnelly RF, Walsh M, Dolan OM, McLoone S, McKenna K, McCarron PA. Aminolaevulinic acid diffusion characteristics in 'in vitro' normal human skin and actinic keratosis: implications for topical photodynamic therapy. Photodermatol Photoimmunol Photomed. 2008 Abstract
  4. New Zealand Datasheet. Methyl aminolevulinate. Drug Summary. 2008 Full text (in our servers)
  5. SNS. Aminolevulinato de metilo (ALM). Información Terapéutica. 2005 Full text (in our servers)

Total visits

1,919

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM